A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
NCT ID: NCT05800327
Last Updated: 2023-04-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE3
Total Enrollment
261 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-12-07
Study Completion Date
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a two-stage study of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of various doses of levilimab when administered intravenously and subcutaneously to healthy subjects and subjects with active rheumatoid arthritis resistant to methotrexate monotherapy.
Aim of the Stage 1 is to study the tolerability, safety, immunogenicity, and main pharmacokinetic and pharmacodynamic parameters of levilimab after its single subcutaneous or intravenous administration at ascending doses to healthy subjects.
Aim of the Stage 2 is to confirm the efficacy and safety of levilimab 648 mg IV Q4W in combination with methotrexate and levilimab 324 mg SC Q2W in combination with methotrexate in subjects with active rheumatoid arthritis, resistant to methotrexate monotherapy.
Aim of the Stage 1 is to study the tolerability, safety, immunogenicity, and main pharmacokinetic and pharmacodynamic parameters of levilimab after its single subcutaneous or intravenous administration at ascending doses to healthy subjects.
Aim of the Stage 2 is to confirm the efficacy and safety of levilimab 648 mg IV Q4W in combination with methotrexate and levilimab 324 mg SC Q2W in combination with methotrexate in subjects with active rheumatoid arthritis, resistant to methotrexate monotherapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.
NCT00036387
Arthritis, Rheumatoid
COMPLETED
PHASE3
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
NCT03885037
Rheumatoid Arthritis
COMPLETED
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
NCT01050998
Rheumatoid Arthritis
COMPLETED
PHASE2
A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis
NCT00236028
Rheumatoid Arthritis
COMPLETED
PHASE3
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
NCT02097524
Rheumatoid Arthritis
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stage 1: there are 3 dose levels and 5 cohorts. The subjects will be followed up for up to 71 days after the IP administration.
Stage 2: the main period of the study (Weeks 0-24) is blinded; study subjects will receive levilimab with placebo. At Week 24 the study will become open-label and all subjects will continue to receive levilimab. At week 28 patients who achieved the RA remission at week 24 will be switched to maintenance therapy of levilimab and will receive it through Week 52. Subjects who do not achieve remission at Week 24, will continue to receive levilimab from Week 28 to Week 52 inclusive corresponding to their treatment group.
Stage 2: the main period of the study (Weeks 0-24) is blinded; study subjects will receive levilimab with placebo. At Week 24 the study will become open-label and all subjects will continue to receive levilimab. At week 28 patients who achieved the RA remission at week 24 will be switched to maintenance therapy of levilimab and will receive it through Week 52. Subjects who do not achieve remission at Week 24, will continue to receive levilimab from Week 28 to Week 52 inclusive corresponding to their treatment group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Rheumatoid Arthritis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
The study design assumes two sequential stages corresponding to Phase I and Phase III studies.
Stage 1 This is an open-label, single-center, non-randomized cohort study of the safety and tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single intravenous or subcutaneous levilimab injections administered to healthy subjects at ascending doses (modified 3+3 design).
Stage 2 This is a randomized, comparative, double-blind, controlled clinical study to assess efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of levilimab when administered at repeated intravenous or subcutaneous doses in combination with methotrexate in subjects with active rheumatoid arthritis resistant to methotrexate monotherapy.
Stage 1 This is an open-label, single-center, non-randomized cohort study of the safety and tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single intravenous or subcutaneous levilimab injections administered to healthy subjects at ascending doses (modified 3+3 design).
Stage 2 This is a randomized, comparative, double-blind, controlled clinical study to assess efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of levilimab when administered at repeated intravenous or subcutaneous doses in combination with methotrexate in subjects with active rheumatoid arthritis resistant to methotrexate monotherapy.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LVL162 group
Levilimab 162 mg SC QW plus placebo starting from Week 0.
Group Type
EXPERIMENTAL
Levilimab
Intervention Type
DRUG
Subcutaneous or intravenous injection of levilimab with placebo.
LVL324 group
Levilimab 324 mg SC Q2W plus placebo starting from Week 0.
Group Type
EXPERIMENTAL
Levilimab
Intervention Type
DRUG
Subcutaneous or intravenous injection of levilimab with placebo.
LVL648 group
levilimab 648 mg IV Q4W plus placebo starting from Week 0.
Group Type
EXPERIMENTAL
Levilimab
Intervention Type
DRUG
Subcutaneous or intravenous injection of levilimab with placebo.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levilimab
Subcutaneous or intravenous injection of levilimab with placebo.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed Informed Consent Form for participation in the study.
2. Malegender.
3. Age 18-45 inclusive at the time of signing the ICF.
4. Healthy status confirmed by the history, physical examination, and laboratory parameters.
5. The absence of a history and signs of alcohol abuse or substance addiction at the time of signing the ICF, and a negative alcohol saliva screening test in combination with a negative urine drug test.
6. The ability of the subject to follow the Protocol procedures, according to the Investigator.
7. The readiness of the subject and their sexual partners with a childbearing potential to use reliable contraceptive measures from the date of signing the informed consent form throughout the study period and for 4 weeks after the administration of the investigational product. This requirement does not apply to the subjects and their partners who have undergone operative sterilization or the female partners of a subject who have been menopausal for more than 2 years.
8. Readiness not to drink alcohol within 24 hours prior to and 70 days after the administration of the investigational product.
1. Signed ICF for participation in the study.
2. Men and women aged ≥ 18 on the ICF signing day.
3. Rheumatoid arthritis that meets the ACR 2010 criteria, confirmed not less than 24 weeks before the ICF signing date. In the event that a subject has been diagnosed with rheumatoid arthritis in accordance with the ACR 1987 criteria, the physician-investigator must confirm the diagnosis in accordance with the ACR 2010 criteria during the screening period, with this information included in the primary documentation, if this has not been done previously and is not documented.
4. Methotrexate therapy during the 12 weeks prior to the ICF signing date.
5. Use of methotrexate at a stable dose during the 4 weeks prior to the ICF signing date (the methotrexate dose should be 15-25 mg per week, methotrexate dose of 10 mg may be used in case of intolerability/toxicity of a higher dose).
6. Failure of methotrexate when used over the 12 weeks before the ICF signing date (according to the Investigator).
7. Swollen joint count ≥ 6 (out of 66); tender joint count ≥ 6 (out of 68).
8. The presence of at least one of three criteria: 1) CRP ≥ 10 mg/L, 2) ESR ≥ 28 mm/h (Westergren method / capillary photometry), 3) morning stiffness that lasts longer than 45 minutes.
9. The ability of the subject to follow the Protocol procedures, according to the Investigator.
10. The readiness of the subject and their sexual partners with a childbearing potential to use reliable contraceptive measures from the date of signing the informed consent form throughout the study period and for 4 weeks after the administration of the last dose of the investigational product. This requirement does not apply to the subjects and their partners who have undergone operative sterilization or females who have been menopausal for more than 2 years.
2. Malegender.
3. Age 18-45 inclusive at the time of signing the ICF.
4. Healthy status confirmed by the history, physical examination, and laboratory parameters.
5. The absence of a history and signs of alcohol abuse or substance addiction at the time of signing the ICF, and a negative alcohol saliva screening test in combination with a negative urine drug test.
6. The ability of the subject to follow the Protocol procedures, according to the Investigator.
7. The readiness of the subject and their sexual partners with a childbearing potential to use reliable contraceptive measures from the date of signing the informed consent form throughout the study period and for 4 weeks after the administration of the investigational product. This requirement does not apply to the subjects and their partners who have undergone operative sterilization or the female partners of a subject who have been menopausal for more than 2 years.
8. Readiness not to drink alcohol within 24 hours prior to and 70 days after the administration of the investigational product.
1. Signed ICF for participation in the study.
2. Men and women aged ≥ 18 on the ICF signing day.
3. Rheumatoid arthritis that meets the ACR 2010 criteria, confirmed not less than 24 weeks before the ICF signing date. In the event that a subject has been diagnosed with rheumatoid arthritis in accordance with the ACR 1987 criteria, the physician-investigator must confirm the diagnosis in accordance with the ACR 2010 criteria during the screening period, with this information included in the primary documentation, if this has not been done previously and is not documented.
4. Methotrexate therapy during the 12 weeks prior to the ICF signing date.
5. Use of methotrexate at a stable dose during the 4 weeks prior to the ICF signing date (the methotrexate dose should be 15-25 mg per week, methotrexate dose of 10 mg may be used in case of intolerability/toxicity of a higher dose).
6. Failure of methotrexate when used over the 12 weeks before the ICF signing date (according to the Investigator).
7. Swollen joint count ≥ 6 (out of 66); tender joint count ≥ 6 (out of 68).
8. The presence of at least one of three criteria: 1) CRP ≥ 10 mg/L, 2) ESR ≥ 28 mm/h (Westergren method / capillary photometry), 3) morning stiffness that lasts longer than 45 minutes.
9. The ability of the subject to follow the Protocol procedures, according to the Investigator.
10. The readiness of the subject and their sexual partners with a childbearing potential to use reliable contraceptive measures from the date of signing the informed consent form throughout the study period and for 4 weeks after the administration of the last dose of the investigational product. This requirement does not apply to the subjects and their partners who have undergone operative sterilization or females who have been menopausal for more than 2 years.
Exclusion Criteria
1. A history of treatment with the products containing monoclonal antibodies to interleukin 6 or its receptor.
2. A History of severe hypersensitivity reactions (angioneurotic edema, anaphylaxis, or multiple drug allergy).
3. Known allergy or intolerance to monoclonal antibody drugs (murine, chimeric, humanized, or fully human) or any other components of the investigational product.
4. Major surgery within 30 days before the signing of the ICF.
5. Severe infections (including those that required hospitalization or parenteral antibacterial, antiviral, antimycotic, or antiprotozoal agents) within 6 months before signing the ICF.
6. Use of systemic antibacterial, antiviral, antimycotic, or antiprotozoal agents within 2 months before signing the ICF.
7. More than 4 episodes of respiratory infections over the past 6 months before signing the ICF.
8. Impossibility to insert a venous catheter for blood sampling (for example, due to skin disease at venipuncture sites).
9. A history of fever over 40 °C.
10. A history of increased levels of hepatic transaminases above 2.5 x ULN.
11. Epileptic seizures, a history of seizures.
12. Depression, suicidal ideations/attempts at the screening or in the history.
13. Regular oral or parenteral administration of any medicinal products, including over-the-counter drugs, vitamins and dietary supplements, within less than 2 weeks before signing the ICF.
14. Use of medicinal products, including over-the-counter drugs, with a pronounced effect on hemodynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before signing the ICF.
15. Use of medicinal products that affect the immune status (cytokines and their inducers, glucocorticoid hormones, etc.) within 2 months before signing the ICF.
16. BCG vaccination, vaccination with live attenuated vaccines and with any other vaccines within 12, 8 and 4 weeks before signing the ICF, respectively, as well as during screening.
17. Standard laboratory and investigation abnormalities.
18. Smoking over 10 cigarettes a day.
19. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 50 mL of spirits) or a history of alcoholism, drug addiction, or drug abuse.
20. Donation of 450 mL or more of blood or plasma within 2 months prior to signing the ICF.
21. Participation in clinical trials of medicinal products within 2 months before signing the ICF or concurrent participation in other clinical trials.
22. Previous participation in the same clinical trial (excluding subjects who dropped out at screening and did not receive the IP).
1. Previous exposure to tocilizumab or other monoclonal antibodies to the interleukin 6 / interleukin 6 receptor.
2. Previous therapy with Janus kinase inhibitors.
3. Previous exposure to rituximab or other products that cause depletion or suppression of B cell activity.
4. Felty's syndrome (regardless of form).
5. The functional status of the subject is class IV according to the ACR 1991 classification.
6. Known allergy or intolerance to any component of the study drug.
7. Concomitant treatment with the following products:
* the need for prednisolone or its equivalent at an oral dose of more than 10 mg/day;
* the need for oral prednisolone or its equivalent at a dose of ≤10 mg/day if this dose was not stable during the last 4 weeks before signing the ICF (patients who received topical glucocorticoids can be included in the study);
* the need for NSAID use if the NSAID dose was not stable during the last 4 weeks before signing the ICF (the patients who occasionally received NSAIDs for fever or allergic syndrome in case of intercurrent diseases can be included);
* the use of alkylating agents at any time within 12 months before signing the ICF;
* intra-articular administration of glucocorticoids within 4 weeks before signing the ICF;
* vaccination with live or attenuated vaccines at any time within 8 weeks before signing the ICF;
* the use of leflunomide within 8 weeks before signing the ICF;
* therapy with TNF-α inhibitors or T cell co-stimulation blockers within 8 weeks before signing the ICF.
8. Patients with any of the following laboratory findings at screening:
* the content of hemoglobin in the blood \< 80 g/L;
* the number of leukocytes in the blood \< 3.0 × 109/L;
* the number of platelets in the blood \< 100 × 109/L;
* the number of neutrophils in the blood \< 2 × 109/L;
* AST and ALT levels ≥ 1.5 × ULN approved in the laboratory;
* serum creatinine ≥ 1.7 × ULN approved in the laboratory.
9. Positive pregnancy urine test in women at screening (the test is not performed in women who have been menopausal for at least 2 years or who have undergone operative sterilization; any of these conditions must be documented).
10. A confirmed diagnosis or a history of the severe immunodeficiency of any other nature.
11. Diagnosis of HIV infection, hepatitis B, C.
12. Diagnosis of tuberculosis, including a history of tuberculosis.
13. Latent forms of tuberculosis (positive Diaskintest® or positive result of the QuantiFERON®-TB Gold test or T-SPOT.TB test, in the absence of radiographic signs of pulmonary tuberculosis).
14. A history of or current herpes zoster.
15. Documented chickenpox within less than 30 days before signing the ICF.
16. The confirmed diagnosis of another chronic infection (for example, invasive mycoses, histoplasmosis, etc.), which can increase the risk of infectious complications in the opinion of the Investigator.
2. A History of severe hypersensitivity reactions (angioneurotic edema, anaphylaxis, or multiple drug allergy).
3. Known allergy or intolerance to monoclonal antibody drugs (murine, chimeric, humanized, or fully human) or any other components of the investigational product.
4. Major surgery within 30 days before the signing of the ICF.
5. Severe infections (including those that required hospitalization or parenteral antibacterial, antiviral, antimycotic, or antiprotozoal agents) within 6 months before signing the ICF.
6. Use of systemic antibacterial, antiviral, antimycotic, or antiprotozoal agents within 2 months before signing the ICF.
7. More than 4 episodes of respiratory infections over the past 6 months before signing the ICF.
8. Impossibility to insert a venous catheter for blood sampling (for example, due to skin disease at venipuncture sites).
9. A history of fever over 40 °C.
10. A history of increased levels of hepatic transaminases above 2.5 x ULN.
11. Epileptic seizures, a history of seizures.
12. Depression, suicidal ideations/attempts at the screening or in the history.
13. Regular oral or parenteral administration of any medicinal products, including over-the-counter drugs, vitamins and dietary supplements, within less than 2 weeks before signing the ICF.
14. Use of medicinal products, including over-the-counter drugs, with a pronounced effect on hemodynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before signing the ICF.
15. Use of medicinal products that affect the immune status (cytokines and their inducers, glucocorticoid hormones, etc.) within 2 months before signing the ICF.
16. BCG vaccination, vaccination with live attenuated vaccines and with any other vaccines within 12, 8 and 4 weeks before signing the ICF, respectively, as well as during screening.
17. Standard laboratory and investigation abnormalities.
18. Smoking over 10 cigarettes a day.
19. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 50 mL of spirits) or a history of alcoholism, drug addiction, or drug abuse.
20. Donation of 450 mL or more of blood or plasma within 2 months prior to signing the ICF.
21. Participation in clinical trials of medicinal products within 2 months before signing the ICF or concurrent participation in other clinical trials.
22. Previous participation in the same clinical trial (excluding subjects who dropped out at screening and did not receive the IP).
1. Previous exposure to tocilizumab or other monoclonal antibodies to the interleukin 6 / interleukin 6 receptor.
2. Previous therapy with Janus kinase inhibitors.
3. Previous exposure to rituximab or other products that cause depletion or suppression of B cell activity.
4. Felty's syndrome (regardless of form).
5. The functional status of the subject is class IV according to the ACR 1991 classification.
6. Known allergy or intolerance to any component of the study drug.
7. Concomitant treatment with the following products:
* the need for prednisolone or its equivalent at an oral dose of more than 10 mg/day;
* the need for oral prednisolone or its equivalent at a dose of ≤10 mg/day if this dose was not stable during the last 4 weeks before signing the ICF (patients who received topical glucocorticoids can be included in the study);
* the need for NSAID use if the NSAID dose was not stable during the last 4 weeks before signing the ICF (the patients who occasionally received NSAIDs for fever or allergic syndrome in case of intercurrent diseases can be included);
* the use of alkylating agents at any time within 12 months before signing the ICF;
* intra-articular administration of glucocorticoids within 4 weeks before signing the ICF;
* vaccination with live or attenuated vaccines at any time within 8 weeks before signing the ICF;
* the use of leflunomide within 8 weeks before signing the ICF;
* therapy with TNF-α inhibitors or T cell co-stimulation blockers within 8 weeks before signing the ICF.
8. Patients with any of the following laboratory findings at screening:
* the content of hemoglobin in the blood \< 80 g/L;
* the number of leukocytes in the blood \< 3.0 × 109/L;
* the number of platelets in the blood \< 100 × 109/L;
* the number of neutrophils in the blood \< 2 × 109/L;
* AST and ALT levels ≥ 1.5 × ULN approved in the laboratory;
* serum creatinine ≥ 1.7 × ULN approved in the laboratory.
9. Positive pregnancy urine test in women at screening (the test is not performed in women who have been menopausal for at least 2 years or who have undergone operative sterilization; any of these conditions must be documented).
10. A confirmed diagnosis or a history of the severe immunodeficiency of any other nature.
11. Diagnosis of HIV infection, hepatitis B, C.
12. Diagnosis of tuberculosis, including a history of tuberculosis.
13. Latent forms of tuberculosis (positive Diaskintest® or positive result of the QuantiFERON®-TB Gold test or T-SPOT.TB test, in the absence of radiographic signs of pulmonary tuberculosis).
14. A history of or current herpes zoster.
15. Documented chickenpox within less than 30 days before signing the ICF.
16. The confirmed diagnosis of another chronic infection (for example, invasive mycoses, histoplasmosis, etc.), which can increase the risk of infectious complications in the opinion of the Investigator.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocad
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
X7 Clinical Research
Saint Petersburg, , Russia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Russia
References
Explore related publications, articles, or registry entries linked to this study.
Lomakin NV, Bakirov BA, Protsenko DN, Mazurov VI, Musaev GH, Moiseeva OM, Pasechnik ES, Popov VV, Smolyarchuk EA, Gordeev IG, Gilyarov MY, Fomina DS, Seleznev AI, Linkova YN, Dokukina EA, Eremeeva AV, Pukhtinskaia PS, Morozova MA, Zinkina-Orikhan AV, Lutckii AA. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm Res. 2021 Dec;70(10-12):1233-1246. doi: 10.1007/s00011-021-01507-5. Epub 2021 Sep 29.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCD-089-5/LUNAR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects
NCT02705989
COMPLETED
PHASE1
A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
NCT00785928
COMPLETED
PHASE2
A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis
NCT01026519
COMPLETED
PHASE1
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
NCT00883896
COMPLETED
PHASE2
Sarilumab Effect on the Pharmacokinetics of Simvastatin
NCT02017639
COMPLETED
PHASE1
A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
NCT00689728
COMPLETED
PHASE2
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis
NCT06175338
ACTIVE_NOT_RECRUITING
PHASE1
A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis
NCT01317797
COMPLETED
PHASE1
Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis
NCT01990157
COMPLETED
PHASE1/PHASE2
Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis
NCT01850680
COMPLETED
PHASE1
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
NCT04779892
COMPLETED
PHASE1
A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
NCT01706926
COMPLETED
PHASE2
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
NCT00380744
COMPLETED
PHASE1/PHASE2
Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
NCT00326339
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
NCT01225393
COMPLETED
PHASE2
Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis
NCT00269867
COMPLETED
PHASE3
A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis
NCT01987479
COMPLETED
PHASE3
Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
NCT02858492
COMPLETED
PHASE2
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis
NCT02531178
COMPLETED
PHASE1
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
NCT01526057
COMPLETED
PHASE2
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
NCT02001987
COMPLETED
PHASE3
A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis
NCT02287922
COMPLETED
PHASE2
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT05638854
RECRUITING
PHASE1
Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
NCT02638948
COMPLETED
PHASE2